Skip to content
Search
Black Sea WireGlobal economics & markets, curated and explained
Black Sea Wire

Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s And Obesity

FForbesBy Bruce Y. Lee, Senior ContributorOriginally published: Added to Black Sea Wire:
Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s And Obesity
Image: Forbes

Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand

Read the full story on Forbes →
ShareXLinkedInFacebookTelegram

Related stories